TABLE 3.
Use of specific ART treatments by country of residence, 2006–2013, n (%).
| Rank | Country | ART cycles | Oocyte donor cycles | Gestational carrier cycles | PGD/PGS cycles | ICSI cycles |
|---|---|---|---|---|---|---|
| 1 | United States | 1,211,072 | 128,693 (10.6) | 19,915 (1.6) | 39,963 (5.3) | 585,483 (74.6) |
| 2 | Canada | 5,669 | 2,655 (46.8) | 244 (4.3) | 845 (25.1) | 3,129 (85.1) |
| 3 | Mexico | 3,367 | 416 (12.4) | 66 (2.0) | 159 (6.4) | 1,556 (62.7) |
| 4 | United Kingdom | 2,422 | 1,251 (51.7) | 281 (11.6) | 302 (20.8) | 1,291 (82.4) |
| 5 | Japan | 2,268 | 2,059 (90.8) | 114 (5.0) | 105 (9.1) | 1,099 (94.5) |
| 6 | People’s Republic of China | 1,539 | 380 (24.7) | 341 (22.2) | 348 (40.0) | 890 (91.8) |
| 7 | Australia | 1,040 | 696 (66.9) | 228 (21.9) | 172 (26.5) | 624 (91.2) |
| 8 | France | 648 | 401 (61.9) | 313 (48.3) | 61 (16.5) | 319 (81.0) |
| 9 | Italy | 479 | 192 (40.1) | 116 (24.2) | 29 (9.6) | 253 (82.4) |
| 10 | Germany | 440 | 199 (45.2) | 188 (42.7) | 50 (19.9) | 247 (90.8) |
| 11 | Spain | 396 | 210 (53.0) | 195 (49.2) | 81 (34.2) | 229 (92.3) |
| 12 | Israel | 283 | 201 (71.0) | 147 (51.9) | 22 (13.7) | 122 (73.9) |
| 13 | Dominican Republic | 281 | 44 (15.7) | (0) | 11 (5.5) | 183 (90.6) |
| 14 | Bahamas | 277 | 68 (24.5) | 7 (2.5) | 12 (6.7) | 154 (84.6) |
| 15 | Switzerland | 274 | 111 (40.5) | 53 (19.3) | 23 (14.9) | 124 (79.0) |
| 16 | Nigeria | 268 | 70 (26.1) | 16 (6.0) | 37 (22.6) | 162 (91.0) |
| 17 | New Zealand | 234 | 193 (82.5) | 19 (8.1) | 31 (21.4) | 127 (85.8) |
| 18 | Ireland | 213 | 105 (49.3) | 63 (29.6) | 23 (17.7) | 113 (78.5) |
| 19 | Sweden | 208 | 116 (55.8) | 99 (47.6) | 18 (16.5) | 71 (58.2) |
| 20 | United Arab Emirates | 177 | 53 (29.9) | 17 (9.6) | 30 (27.0) | 103 (91.2) |
| 21 | Norway | 152 | 62 (40.8) | 67 (44.1) | 26 (27.1) | 75 (71.4) |
| 22 | Netherlands | 144 | 66 (45.8) | 44 (30.6) | 8 (9.9) | 77 (87.5) |
| 23 | Argentina | 142 | 47 (33.1) | 50 (35.2) | 13 (14.9) | 84 (92.3) |
| 24 | India | 131 | 7 (5.3) | –a | 26 (27.1) | 94 (94.0) |
| 25 | Qatar | 125 | (0) | (0) | 15 (17.6) | 85 (100) |
Note: The percentages of oocyte donor and gestational carrier cycles were calculated among all ART cycles from the specified country (column 3). The percentages of cycles using PGD/PGS and ISCI were calculated among each country’s share of the 797,211 (PGD/PGS) and 826,153 (ICSI) cycles for which these fields were reported, because PGD/PGS and ICSI status were not collected for frozen and cancelled cycles. Abbreviations as in Tables 1 and 2.
a
To protect confidentiality, values from 1 to 4 are suppressed.
Levine. ART use in the U.S. by nonresidents. Fertil Steril 2017.